| 03-Aug-12 |
| Glenmark Pharmaceuticals Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from July 23, 2012 to August 03, 2012 (both days inclusive) for the purpose of Payment of Dividend & 34th Annual General Meeting (AGM) of the Company to be held on August 03, 2012.
Glenmark Pharmaceuticals Ltd has informed BSE that the 34th Annual General Meeting (AGM) of the Company will be held August 03, 2012.
(As Per BSE Announcement Website Dated on 09/07/2012)
Glenmark Pharmaceuticals Ltd has informed BSE that at the Annual General meeting (AGM) held on August 03, 2012, the Shareholders have approved the following:
- Dividend of Rs. 2 per share of Re. 1 each (200%) on the Equity Share Capital of the company for the financial year ended 2011-12.
(As Pwr BSE Announcement Website Dated on 03/08/2012)
Glenmark Pharmaceuticals Ltd has informed BSE that the 34th Annual General Meeting (AGM) of the Company was held on August 03, 2012, under Clause 35A.
(As Per BSE Announcement Dated on 07.08.2012) |
| 11-Aug-11 |
| Glenmark Pharmaceuticals Limited has informed the Exchange that the Register of Members and the Share Transfer Books of the Company will remain
closed from August 01, 2011 to August 11, 2011 (both days inclusive) for the purpose of the Annual Closure for the Annual General Meeting scheduled to be held on August 11, 2011 and also for determining the names of the shareholders to whom the dividend which if declared at the Annual General Meeting i payable.
Glenmark Pharmaceuticals Ltd has informed BSE that the members at the Annual General Meeting (AGM) of the Company held on August 11, 2011, inter alia, have approved the Dividend of Re. 0.40 per share of Re. 1 each (40%) on the Equity Share Capital of the Company for the financial year ended 2010-2011.
(As Per BSE Announcement Website dated on 11.08.2011)
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of the proceedings of the 33rd Annual General Meeting of the Company held on August 11, 2011 inter alia, have also accorded to the following:
1. Adoption of the Audited Accounts for the year ended March 31, 2011 and the Report of Board of Directors and the Auditors thereon.
2. Declaration of Dividend of Re. 0.40 per
Equity Share of Re. 1/- each (i.e. 40%) as recommended by the Board of Directors for the year ended March 31, 2011.
3. Re-appointment of Mrs. B. E. Saldanha, Mrs. Cheryl Pinto & Mr. D. R. Mehta as Directors of the Company.
4. Appointment of M/s. Walker, Chandiok & Co. Chartered Accountants, as the Statutory Auditors of the Company hold office from the conclusion
of this Annual General Meeting (AGM) until the conclusion of the next Annual General Meeting (AGM) on a remuneration, terms & conditions.
(As Per BSE Announcement Dated on 30.08.2011) |
| 27-Sep-10 |
| Glenmark Pharmaceuticals Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 20, 2010 to September 27, 2010 (both days inclusive) for the purpose of Payment of Dividend & 32nd Annual General Meeting (AGM) of the Company to be held on September 27, 2010.
Glenmark Pharmaceuticals Ltd has informed BSE that the Shareholders at the Annual General Meeting (AGM) of the Company held on September 27, 2010, have approved the following:
1. Final Dividend @ 40% on the Equity Share Capital of the Company for the financial year ended 2009-2010.
2. Appointment of Walker, Chandiok & Co. Chartered Accountants as Statutory Auditors of the Company for the Financial Year 2010-2011.
(As Per BSE Announcement Website dated on 27.09.2010)
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of the proceedings of the 32nd Annual General Meeting (AGM) of the Company held on September 27, 2010.
(As Per BSE Announcement Dated on 08.10.2010) |
| 25-Sep-09 |
| Glenmark Pharmaceuticals Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 14, 2009 to September 25, 2009 (both days inclusive) for the purpose of Payment of Dividend & 31st Annual General Meeting (AGM) of the Company to be held on September 25, 2009.
Glenmark Pharmaceuticals Ltd has informed BSE that the members at the 31st Annual General Meeting (AGM) of the Company held on September 25, 2009, inter alia, have accorded to the following:
1. Adoption of the Audited Accounts for the year ended March 31, 2009 and the Report of Board of Directors and the Auditors thereon.
2. Declaration of Dividend of Re. 0.40 per Equity Shares of Re. 1/- each (i.e. 40%) for the year ended March 31, 2009.
3. Re-appointment of Mr. Gracias Saldanha & Mr. N. B. Desai as Directors of the Company.
4. Appointment of M/s. Price Waterhouse, Chartered Accountants, Mumbai, as the Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting on a remuneration, terms & conditions.
5. Appointment of Mrs. B. E. Saldanha & Mr. D. R. Mehta as Directors of the Company.
(As Per BSE Announcement Dated on 26/10/2009) |
| 26-Sep-08 |
| Glenmark Pharmaceuticals Ltd. has informed the Exchange that
The Annual General Meeting of the Company will be held on September 26, 2008.
Glenmark Pharmaceuticals Ltd has informed BSE that the members at the Annual General Meeting (AGM) of the Company held on September 26, 2008, inter alia, have accorded to the following:
1. Adoption of the Audited Accounts for the year ended March 31, 2008 and the Report of Board of Directors and the Auditors thereon.
2. Confirmation of Interim Dividend paid on Equity Shares @ 70% on the paid-up Equity Share Capital of the Company for the year ended March 31, 2008 as final dividend.
3. Re-appointment of Mrs. B E Saldanha, Mr. Rajesh V Desai & Mr. A S Mohanty as Directors of the Company.
4. Appointment of M/s. Price Waterhouse, Chartered Accountants, Mumbai, as the Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting on a remuneration, terms & conditions.
5. Authority to the Board to issue, offer and allot Equity shares /warrants and / or instruments convertible into Equity shares optionally or otherwise including but not limited to Global Depository Receipts (GDR's) / American Depository Receipts (ADR's) / Foreign Currency Convertible Bonds (FCCB's) or any combination thereof ("Securities") for an aggregate sum upto US$ 250 million with a green shoe option of 15% or equivalent in Indian and / or any other currency (ies) inclusive of such premium, as may be permitted by the Ministry of Finance / such other authorities directly to Indian / Foreign / Resident
/ Non-resident Investors (whether Institutions, Incorporate Bodies, Mutual Funds / Trusts / Foreign Institutional Investors / Banks and / or individuals, or otherwise and whether or not such investors are members, promoters, directors or their relatives of the Company) through Public Issue(s), Private Placement(s) or a combination thereof or through Qualified Institutional Placement (QIP) in terms of Chapter XIII A of the SEBI (Disclosure and Investor Protection) Guidelines, 2000 as amended from time to time at such time or times, in such tranche or tranches, at such price or prices at a discount or premium to market price or prices in such manner and on such terms and conditions as may be decided and deemed appropriate by the Board at the time of such issue or allotment of considering the prevailing market conditions and other relevant factors, wherever necessary in consultation with the Lead Managers, Underwriters, advisors or through the subsidiaries, including by way of Initial Public Offer in US or other countries, so as to enable the Company to get listed at any Stock xchanges in India and / or Luxemburg / London / New York / Singapore / Hong Kong Stock Exchanges and / or any of the Overseas Stock Exchanges, subject to necessary provisions & approvals.
(As Per BSE Announcement Website dated on 06.10.2008) |